Request Clinical Starter Kits for Your Patients Today! Request Now

Are you a clinician?

This is a clinician-only website.
By entering, you acknowledge that you're a clinician.

EVNol SupraBio™ supplementation increases tocotrienols in the brain and other vital organs, study shows


  • EVNol SupraBio™ mixed tocotrienols significantly increases tocotrienol levels in blood, skin, adipose, brain, cardiac muscle, and liver over time
  • Effective dosage is 200 mg/day, twice daily, for at least 12 weeks
  • Supplementation may also offer clinical value for liver transplant patients


This study was designed to measure the tissue and organ uptake of supplemental vitamin E given either in the tocopherol (TCP) or tocotrienol (TE) form, the two chemical classes of natural vitamin E.

For this study, researchers studied a total of 80 adults who were given either EVNol SupraBio™ mixed tocotrienols* (200 mg, twice daily) or alpha-tocopherol (200 mg, twice daily). Skin and blood vitamin E levels were determined from healthy participants (n=16) following 12 weeks of oral supplementation. Vital organ vitamin E levels were determined by HPLC in adipose, brain, cardiac muscle, and liver tissue of surgical patients following supplementation (mean duration, 20 wk; range, 1-96 wk). Participant compliance with supplementation was reported to be over 90%.

Results indicate that oral supplementation of TE significantly increased levels of TE in blood, skin, adipose, brain, cardiac muscle, and liver over time. Moreover, alpha-TE was delivered to the brain at a level reported to be neuroprotective in experimental models of stroke.

In prospective liver transplantation patients, oral TE lowered the model for end-stage liver disease (MELD) score in 50% of patients supplemented, while only 20% of TCP-supplemented patients showed a reduction in MELD score.

These findings indicate that EVNol SupraBio™ mixed tocotrienols (200 mg, twice daily) increases the level of tocotrienols in vital organs, including brain, and may offer clinical value for liver transplant patients.

*The study treatment is identified as TOCOVID SupraBio™ softgels, which is another brand name for EVNol SupraBio™ softgels. EVNol SupraBio is a trademark of ExcelVite Inc and protected by US Patent No – 6,596,306 and 7,211,274.


Patel V, Rink C, Gordillo GM, et al. Oral tocotrienols are transported to human tissues and delay the progression of the model for end-stage liver disease score in patients. J Nutr. 2012;142(3):513-9.

PMID: 22298568